Evinova is a global healthtech business within life sciences. We are here to empower the sector to accelerate the delivery of better health outcomes. Through our unique application of science-based expertise, evidence-led rigour, and human experience-driven insight, our digital solutions are deliberately designed so that everyone can reach better health outcomes together. Evinova is a separate business within the AstraZeneca group. For more information, go to https://evinova.com/

TxSphere is a medical device designer specializing in drug delivery systems for combination products. Spun off from Intuvie LLC, TxSphere’s wearable platform is powered by proprietary linear peristaltic technology for precise, reliable infusion. Its modular design features a reusable pump and disposable drug module with automatic cannula insertion. The Vista device supports delivery from standard vials and cartridges, while Horizon III offers an internal reservoir for enhanced portability. With customizable reservoir sizes, flow rates, and configurations, TxSphere wearables are built to meet diverse therapeutic needs across a wide range of clinical applications. To learn more, please visit www.tx2sphere.com

G2GBIO is a clinical-stage biotech company specializing in long-acting injectables of various small molecule and peptide drugs. Its proprietary platform technology, InnoLAMP, enables the mass production of homogeneous microsphere with high drug loading (~60% for small molecules and ~50% for for peptides), improved bioavailability, and less injection site reactions.

ClostraBio is a spin-out of the University of Chicago focused on developing a novel nanoparticle platform to deliver small molecules to the lower gut. Our polymeric oral prodrug platform was initially designed to overcome challenges with dosing the short-chain fatty acid butyrate. Following a pre-IND meeting with FDA and completion of 28-day toxicology studies showing the polymer backbone is safe, we have now synthesized polymers that release other SCFAs, non-SCFA bacterial metabolites, and other non-metabolite small molecules. We are currently seeking partners interested in utilizing our oral nanoparticle prodrug approach to enable gut-targeted delivery, sustained release, and soluble dosage forms, while creating opportunities to extend patent life. For more information, visit https://clostrabio.com/index.html.

SOLUtion Medical is a specialty pharmaceutical company with a fully integrated supply chain for reconstitution products. Our proprietary delivery device portfolio affords patients, caregivers, and clinicians device options to fit within their lifestyles at home and in multiple healthcare settings. For more information, please visit https://www.solutionmedco.com

Grove transforms clinical trial recruitment with AI-accelerated Participant Relationship Management (PRM). Our PRM streamlines patient engagement from pre-screening to post-trial follow-ups by enabling clinical research organizations to make data-driven recruitment decisions and automate manual tasks. By leveraging AI, we drive efficiency, accuracy, and scalability in patient recruitment, enabling faster and higher quality clinical trials. For more information, go to https://grovetrials.com/

Lesjöfors manufactures and supplies the medical industry with springs and pressings from wire or strip material for disposable medical products, medical equipment and hygiene-related products. We have an expansive network of production plants around the world with exceptional expertise and equipment dedicated to the medical sector. Regardless of the quantity and application, we offer innovative solutions for manufacturing, cleanliness, packaging and automation. Our medical technological high-quality standards are achieved through state-of-the-art production facilities and production technology, a large range of products, use of the latest laboratory technology and certified standards. For more information, please visit https://www.lesjoforsab.com/industries/medical/

Oxford Medical Products (OMP) is a UK-based biotech that has developed a gastroretentive, hydrogel platform technology. The technology is currently in phase 2 trials as a stand-alone anti-obesity treatment and is also being developed as an oral drug delivery system for both small molecules and peptides. The technology may overcome common oral delivery challenges, such as poor bioavailability and high peak-to-trough ratios, by facilitating sustained release from the stomach. Notably, the technology is ideally suited to delivering cardiometabolic drugs due to its inherent appetite-suppressing capabilities. The technology is also applicable to stomach-targeted and stomach-absorbed drugs due to prolonged gastric retention and gastric mucosal contact. For more information, visit https://www.oxfordmedicalproducts.com/

Interim Visits is an online quarterly magazine that focuses on clinical research. Here you will find articles for those interested in learning more about clinical research, those considering participating in clinical trials, and clinical research professionals. We named the magazine Interim Visits because most of the data from a clinical trial is obtained, reviewed and verified during the interim visits when the data is reviewed and verified.

For more information, go to https://interimvisits.com/

Dr. Vince Clinical Research (DVCR) is a full-service contract research organization (CRO) specializing in early phase trials in both healthy normal volunteers and patient populations across a wide range of trial designs and therapeutic areas such as neuroscience, substance abuse, pain, cardiometabolic disorders, infectious diseases and many others. CRO services include project management, data management, biostatistics, statistical programming, PK/PD analysis, medical writing, monitoring as well as site feasibility and management for multi-site trials. Additionally, DVCR operates one of the most innovative and technologically advanced clinical pharmacology units in the world with over 90 beds for overnight confinement, a cGMP compliant pharmacy as well as luxurious amenities to support diverse study participant recruitment and retention. By leveraging technology and one of the country’s most experienced leadership teams in early clinical development, DVCR provides Smarter Faster Data® to their biopharmaceutical clients. For more information, please visit https://sponsors.drvince.com/

QurCan Therapeutics, a University of Toronto spin-off biotech company, has developed a novel hybrid polymer-lipid nanoparticle technology called TERP platform, that enables non-immunogenic and CNS delivery of RNA molecules. QurCan is leveraging this disruptive TERP nanoparticle technology to advance innovative nucleotide therapeutics for individuals affected by genetically driven neurodegenerative diseases. For more information, please visit www.qurcan.com

Diligent Pharma is redefining vendor qualification and management within the clinical trial landscape through its tech-enabled, centralized quality and risk management platform. By integrating regulatory compliance expertise with a secure technology solution, Diligent provides a one-stop resource for managing vendor discovery, risk assessment, selection, and oversight activities. The Diligent platform, firmly rooted in the ICH Vendor Risk Management Framework, houses qualification packages and risk assessments for hundreds of vendors across 32 clinical trial service categories. Global regulatory authorities accept Diligent's centralized model as a valid approach to vendor qualification and oversight, allowing sponsors to save significant time by eliminating redundant steps through a system that ensures compliance and supports smarter, data-informed decision-making. For more information, go to www.diligentpharma.com.